cinqair- reslizumab injection, solution, concentrate
teva respiratory, llc - reslizumab (unii: 35a26e427h) (reslizumab - unii:35a26e427h) - reslizumab 10 mg in 1 ml - cinqair® is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype [see clinical studies (14)] . limitation of use: - cinqair is not indicated for treatment of other eosinophilic conditions. - cinqair is not indicated for the relief of acute bronchospasm or status asthmaticus [see warnings and precautions (5.2)] . cinqair is contraindicated in patients who have known hypersensitivity to reslizumab or any of its excipients [see warnings and precautions (5.1)] . risk summary the data on pregnancy exposure from the clinical trials are insufficient to inform on drug-associated risk. monoclonal antibodies, such as reslizumab, are transported across the placenta in a linear fashion as pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimester of pregnancy. reslizumab has a long half-life [see clinical pharmacology (12.3)] . this should be taken into consideration. in anima
cinqair
teva israel ltd - reslizumab - concentrate for solution for infusion - reslizumab 10 mg / 1 ml - reslizumab - cinqair is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype [see clinical studies (14)].limitation of use:• cinqair is not indicated for treatment of other eosinophilic conditions.• cinqair is not indicated for the relief of acute bronchospasm or status asthmaticus
cinqaero
teva b.v. - reslizumab - asthma - other systemic drugs for obstructive airway diseases, - cinqaero is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
cinqaero reslizumab 100 mg/10 ml concentrated solution for intraveous infusion vial
teva pharma australia pty ltd - reslizumab -
cinqair reslizumab 100 mg/10 ml concentrated solution for intravenous infusion vial
teva pharma australia pty ltd - reslizumab, quantity: 100 mg - injection, concentrated - excipient ingredients: sodium acetate trihydrate; glacial acetic acid; water for injections; sucrose - cinqair is indicated as add-on therapy in adult patients with severe eosinophilic asthma (blood eosinophil count greater than or equal to 400 cells/?l) (see clinical trials).
cinqair solution
teva canada limited - reslizumab - solution - 10mg - reslizumab 10mg - interleukin antagonists
cinqaero 100mg10ml concentrate for solution for infusion vials
teva uk ltd - reslizumab - solution for infusion - 10mg/1ml
cinqaero 25mg2.5ml concentrate for solution for infusion vials
teva uk ltd - reslizumab - solution for infusion - 10mg/1ml
isocare 1000 mg/g inhalation vapour liquid
animalcare limited - isoflurane - inhalation vapour liquid - 1000 mg/g - reslizumab - avian, canine, equine - food, feline, ferret, gerbils, guinea pigs, hamsters, reptile - neurological preparations
cinqaero 10 mg/ml vial concentrat perfusió 10 ml